For the treatment and control of bleeding episodes occurring in adults and adolescents (12 years of age and older) with hemophilia A or B with inhibitors1

HE’S READY TO MOVE ON

SEVENFACT

The first inhibitor bypassing agent approved in the US in over 20 years2,3
Differs molecularly from the other available rFVIIa4

For the treatment and control of bleeding episodes occurring in adults and adolescents (12 years of age and older) with hemophilia A or B with inhibitors1

HE’S READY TO MOVE ON

SEVENFACT

The first inhibitor bypassing agent approved in the US in over 20 years2,3
Differs molecularly from the other available rFVIIa4

Living with an inhibitor
is unpredictable5-8

Controlling bleeds quickly is of critical concern

Rapid, predictable†, and reliable relief 9

84% of 213 mild/moderate bleeding events achieved sustained bleed control after just one dose of SEVENFACT 225‡9

As seen in the clinical trial.
225 μg/kg initial dosing regimen in the clinical trial.

Dose to achieve your treatment goals for mild/moderate bleeds1

SEVENFACT 225: Starting dose of 225 μg/kg, followed, if necessary, 9 hours later by a 75 μg/kg dose every 3 hours until bleed control

References:

  1. SEVENFACT [Prescribing Information]. HEMA Biologics; 2020.
  2. FDA ACCEPTS FOR REVIEW LFB’S BLA FOR ITS RECOMBINANT FACTOR VII [news release]. Les Ulis (France). LFB News. https://www.groupe-lfb.com/en/news/fda-accepts-for-review-lfbs-bla-for-its-recombinant-factor-vii/. Accessed November 23, 2020. LFB Groupe. 2017.
  3. NovoSeven [Prescribing Information]. Novo Nordisk; 2020.
  4. Biron-Andreani C, Schved J-F. Eptacog beta: a novel recombinant human factor VIIa for the treatment of hemophilia A and B with inhibitors. Expert Rev Hematol. 2019;12(1):21-28.
  5. Salaj PO, Brabec P, Penka M, et al. Effect of rFVIIa dose and time to treatment on patients with haemophilia and inhibitors: analysis of HemoRec registry data from the Czech Republic. Haemophilia. 2009;15:752-759.
  6. Kavakli K, Yesilipek A, Antmen B, et al. The value of early treatment in patients with haemophilia and inhibitors. Haemophilia. 2010;16:487-494.
  7. Morfini M. Rapid rFVIIa enhanced on-demand dosing in haemophilia inhibitor patients. Eur J Haematol. 2016;96:111-118.
  8. Gomez K, Klamroth R, Mahlangu J, et al. Key issues in inhibitor management in patients with haemophilia. Blood Transfus. 2014;12(suppl1):s319-s329.
  9. Data on file. Hema Biologics.